)
)
)
Bound Therapeutics is a pioneering biotechnology company dedicated to the development of RNA-based therapies targeting rare and refractory diseases, with a primary focus on oncology. Our proprietary platform, Magic Bullet Designer (MBD), utilizes advanced artificial intelligence and machine learning algorithms to optimize the tissue-specific delivery of RNA therapeutics, thereby enhancing precision and therapeutic efficacy. Currently in the preclinical stage, our pipeline encompasses novel treatments for aggressive malignancies and genetic disorders, positioning Bound Therapeutics at the forefront of next-generation RNA therapeutics.
Year Founded
2015
Next catalyst (value inflection) update
Complete an IND packet including expanding the preclinical pipeline, manufacturing scale-up, and conducting safety studies in two species
Expected time of next catalyst update
01/09/2026
City
Philadelphia
Country
United States
Company CEO or top company official
Yuanyuan Jin, Co-Founder & COO
Development Phase of Primary Product
Pre-Clinical
Lead Product in Development
We have achieved in vivo proof-of-concept in aggressive breast cancer for our lead molecule BND6482, which targets microRNA-21, a key oncogenic RNA overexpressed in all solid tumors.
Number of Unlicensed Products
2
Therapeutic Area
Platform for Therapeutics
Website
http://www.boundtherapeutics.com